Meningioma Recurrence After Surgery: What It Means for Depo-Provera Claims

Key Points
- Meningiomas linked to Depo-Provera often form at the base of the skull, where complete removal is more difficult and recurrence and repeat surgery are more common.
- The Simpson grade in a surgeon’s operative report describes how completely a meningioma was removed and helps predict whether it may return.
- Women whose meningioma returned after surgery or radiation may qualify to file a Depo-Provera lawsuit and seek compensation for additional treatment.
Why It Matters
Meningiomas linked to Depo-Provera often form at the base of the skull, near the eyes, major nerves, and blood vessels. Tumors in these locations are harder to remove completely. When part of a tumor is left behind, it can grow back. Some women need a second surgery, radiation, or years of MRI monitoring after their first operation. A recurrence can add significant medical costs, lost income, and long-term health effects to a Depo-Provera claim.
Depo-Provera Meningiomas and the Risk of Recurrence
Many women diagnosed with meningioma brain tumors after using the Depo-Provera birth control shot undergo surgery expecting the tumor to be gone for good. For some women, surgery is effect at treating their meningioma. For others, a follow-up MRI shows that the tumor has returned, or that part of it was never removed.
A meningioma recurrence is the regrowth of a tumor after treatment. Research shows that meningiomas linked to progestins such as medroxyprogesterone acetate, the active ingredient in Depo-Provera, tend to grow in locations that make complete removal more difficult.
Women who used Depo-Provera and were diagnosed with meningioma may qualify to file a Depo-Provera lawsuit, whether or not their tumor came back. A recurrence, a second surgery, or added radiation treatment can, however, increase the harm a woman has suffered and the compensation to which she may be entitled.
If you or a loved one used Depo-Provera and were diagnosed with a meningioma brain tumor, including a tumor that returned after surgery, you may be eligible to file a lawsuit and receive compensation. Find out whether you qualify or start your claim today by contacting the lawyers at Hissey Mulderig & Friend toll-free at 1-866-806-8117, or by filling out the free claims submission form.
Why Depo-Provera Meningiomas Are Harder to Remove
Researchers have identified a distinct pattern among meningiomas linked to progestin drugs. A recent medical review of medroxyprogesterone acetate and meningioma found that these tumors often share several features:
- High levels of progesterone receptors
- More than one tumor at the time of diagnosis
- A preferred location in the front and middle portions of the skull base
- Shrinkage after progestin treatment stops
The same review found that the skull base location makes surgery more difficult. As a result, incomplete removal is more common, which leads to more lasting complications, more recurrences, and more repeat operations.
Research from the United States points to the same pattern. In a series of women with long-term Depo-Provera use, 68% had at least one skull base meningioma in the region around the eye socket, the sphenoid bone, or the cavernous sinus. The authors described a progestin meningioma syndrome affecting younger, middle-aged women, who often had multiple tumors.
The skull base is the floor of the skull beneath the brain. Tumors in this area can surround the optic nerves, which carry vision, as well as the carotid arteries and the cavernous sinus, a cluster of veins and nerves that control eye movement. Surgeons often leave part of a tumor attached to these structures rather than risk blindness, stroke, or nerve damage.
Women with multiple meningiomas after Depo-Provera face added complexity, because each tumor may require separate treatment and monitoring.
What the Simpson Grade Means
Neurosurgeons describe how completely a meningioma was removed using the Simpson grading scale, first published in 1957. The grade usually appears in the operative report or the surgeon’s notes.
- Grade I: Complete removal of the tumor, its attachment to the dura (the tough membrane covering the brain), and any abnormal bone
- Grade II: Complete removal of the tumor, with the dural attachment burned (coagulated) rather than cut out
- Grade III: Complete removal of the visible tumor, without removing or coagulating its dural attachment or any tumor in the bone
- Grade IV: Partial removal, leaving some tumor behind
- Grade V: Biopsy or decompression only
In Simpson’s original study, the recurrence rate rose with each grade, from 9% after Grade I removal to 44% after Grade IV removal.
Modern research shows that the relationship depends on where the tumor is located. In an analysis of 931 cranial meningioma surgeries, skull base tumors showed a higher risk of recurrence mainly after Grade IV, or partial, removal. The same study found that operations for recurrent tumors had significantly higher Simpson grades, meaning less complete removal, than first operations.
Recurrence also depends on the tumor’s World Health Organization (WHO) grade, which describes how the cells look under a microscope. Most meningiomas are classified as benign or WHO Grade 1. Grade 2 (atypical) and Grade 3 tumors are more likely to return.
How a Meningioma Recurrence Is Detected
Many meningioma recurrences are found on follow-up MRI scans, often before any symptoms appear. Doctors typically schedule imaging at regular intervals for years after surgery or radiation. This is one reason women with Depo-Provera meningiomas may require lifetime monitoring for brain tumors.
When symptoms do return, they often mirror the original symptoms of the tumor:
- Headaches
- Blurred or double vision
- Seizures
- Numbness or weakness
- Changes in memory, mood, or personality
How Recurrent Meningiomas Are Treated
Treatment for a recurrent meningioma depends on its size, location, growth rate, and WHO grade. The options are generally the same as those used for a first tumor.
Repeat surgery. A second operation may use the same surgical approaches used for Depo-Provera meningiomas the first time. A study of 109 patients who underwent surgery for a first recurrence found that repeat surgery did not generally carry a higher risk of complications than the original operation. However, skull base tumors were about six times more likely to be only partly removed during repeat surgery.
Multiple operations. Some women face more than two surgeries. A study of recurrent skull base meningiomas analyzed 85 operations performed on 65 patients, including second and third reoperations. Higher-grade tumors made up a larger share of the later operations.
Radiation. Radiosurgery and fractionated radiation therapy are commonly used to treat tumor left behind after surgery or tumor that has grown back. The types of radiation treatment used for Depo-Provera meningiomas include Gamma Knife, CyberKnife, and proton therapy.
Observation. A small recurrence that is not growing quickly may be monitored with repeat MRI scans rather than treated right away.
Can a Meningioma Come Back After Stopping Depo-Provera?
Studies have found that some meningiomas shrink after women stop using Depo-Provera. Stopping the shot does not guarantee that a tumor will remain stable.
A published case report described a spheno-orbital meningioma, a tumor involving the bone around the eye socket, that continued to grow within the bone after progestin treatment stopped. The authors concluded that tumor growth inside the bone was not explained by the tumor’s cell activity.
Women who have stopped using Depo-Provera are generally advised to continue the follow-up imaging their doctors recommend.
How a Recurrence Affects a Depo-Provera Lawsuit
A recurrence does not change whether a woman may qualify to file a claim. It can, however, add to the compensation women may recover, including:
- The cost of additional surgery, radiation, and hospital stays
- Ongoing MRI monitoring
- Lost income during a second or third recovery
- Long-term cognitive, emotional, or physical effects
Research supports the last point. A multicenter study published in Neurosurgery found that many meningioma patients still had impaired quality of life, cognitive deficits, and anxiety or depression a median of nine years after treatment. Repeat surgery was associated with worse attention.
The documents that prove a recurrence include operative reports, pathology reports, and follow-up MRI reports. These records show the Simpson grade, the WHO grade, and any regrowth over time. Women do not need to collect these medical records for a Depo-Provera lawsuit on their own before contacting an attorney.
The litigation is also moving quickly. According to a court order in the federal multidistrict litigation, Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement on July 21, 2026, and the parties estimate that roughly 80% of MDL plaintiffs will be eligible. Registration is expected to be completed in November 2026. Women who have not yet filed should review the latest Depo-Provera settlement registration information and speak with a lawyer about their options.
Who Is Eligible to File a Depo-Provera Lawsuit?
Women who used the Depo shot and were later diagnosed with brain tumors may be eligible to file a lawsuit if they meet all of the following case criteria:
- Used Depo-Provera or Depo-SubQ Provera 104 for birth control;
- At least one year (four injections) of Depo-Provera use;
- Diagnosed with a cerebral meningioma brain tumor, including a tumor that recurred after treatment.
If you or a member of your family answered “yes” to all of the above criteria, you may qualify to file a lawsuit and receive compensation.
Frequently Asked Questions About Meningioma Recurrence
Can a meningioma come back after surgery?
Yes. The risk depends on how completely the tumor was removed, where it was located, and its WHO grade. Skull base tumors, which are common among women who used Depo-Provera, are more difficult to remove completely.
What is a Simpson grade?
A Simpson grade is a rating from I to V that describes how completely a surgeon removed a meningioma. Grade I is the most complete removal. Grades IV and V mean that tumor was left behind.
Can a woman file a Depo-Provera lawsuit if her meningioma came back?
Yes. A recurrence does not affect eligibility. Additional surgery, radiation, and monitoring may increase the damages a woman can seek.
Does a second surgery affect the value of a Depo-Provera claim?
A second surgery documents additional medical costs, recovery time, and potential long-term effects. Each of these factors may be considered when the value of a claim is evaluated.
Contact Our Law Firm to Start Your Claim Today
If you or a loved one used the Depo-Provera shot and were diagnosed with a meningioma brain tumor, including a tumor that returned after surgery or radiation, you may be eligible to file a lawsuit and receive compensation.
The lawyers at Hissey Mulderig & Friend have represented women across the U.S. who have been diagnosed with meningioma brain tumors after using the Depo shot. Our law firm has also represented women harmed by other birth control production, including Ortho Evra, Paragard, Yaz and Yasmin, and Mirena.
Find out whether you qualify to file a Depo-Provera claim or start the process of taking legal action today by contacting Hissey Mulderig & Friend toll-free at 1-866-806-8117, or send us a message using the free case evaluation form located at the top of this page.
Last updated on: October 12, 2026

